Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clenbuterol to Target DUX4 in FSHD (Target FSHD): Open Label Safety and Tolerability Study of 3 Doses of Clenbuterol

NCT06721299 is registered in ClinicalTrials.gov with Jeffrey Statland as lead sponsor.

NCT NCT06721299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06721299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clenbuterol to Target DUX4 in FSHD (Target FSHD): Open Label Safety and Tolerability Study of 3 Doses of Clenbuterol
Lead sponsor
Jeffrey Statland
Phase
Phase 1
Overall status
Recruiting
Start date
June 25, 2025
Completion date
July 31, 2028
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

muscular dystrophy, facioscapulohumeral